Jennifer Eileen Adair

Jennifer Eileen Adair, PhD is a Professor in the Department of Genetic and Cellular Medicine at UMass Chan Medical School, with dual appointments in the T.H. Chan School of Medicine. Her research bridges basic science with translational applications in gene and cell therapy.

Dr. Adair earned her BS in Chemistry from Youngstown State University and her PhD in Genetics and Cell Biology from Washington State University. Her academic journey has focused on developing innovative approaches to gene therapy with an increasing emphasis on global accessibility.

Her research program centers on gene therapy development, particularly in hematopoietic stem cell engineering, CRISPR-based gene editing, and manufacturing optimization for cell and gene therapies. Recent work demonstrates a strong commitment to addressing global health disparities, with multiple publications on making gene therapies accessible in low- and middle-income countries through localized manufacturing solutions. Her laboratory investigates fundamental questions about stem cell biology while developing practical applications for genetic disorders including Fanconi anemia.

Analysis of her recent publications (2020-2024) shows a strategic shift toward addressing implementation challenges of gene therapies, with approximately 40% of her work now focused on manufacturing, accessibility, and global health equity issues. Her research combines molecular biology, stem cell engineering, and health systems analysis to create practical solutions for bringing advanced therapies to diverse patient populations worldwide.

Dr. Adair has established herself as a leader in both the technical development of gene therapies and the critical discourse around their global implementation. Her work spans from basic molecular mechanisms to health policy considerations, reflecting a comprehensive approach to advancing the field.

She actively collaborates with international teams to address the translational gap in gene therapy, with recent projects spanning multiple continents and involving partnerships with researchers in India, Africa, and South America. Her laboratory focuses on developing point-of-care manufacturing solutions that could democratize access to these life-saving treatments.